MGTX Buys Back XLRP Gene Therapy for $25 M
$MGTX just announced that it has entered into an asset purchase agreement with $JNJ to acquire back its bota-vec Gene Therapy program for the treatment of X-linked retinitis pigmentosa (XLRP) 🧵👇 for an upfront cash payment of $25M & a one-time regulatory and commercial milestone tied to U.S. approval and sales of bota-vec, as well as a high double-digit royalty on global net sales starting in mid-2029. $XBI
AllogeneTx Stock Plummets After $2 Share Offering
I saw that a lot of people on 𝕏 are surprised by the sharp decline in $ALLO stock price - from $4.3 to $2.2 in one day despite the company’s excellent cema-cel readout 🧵👇. The reason for this decline is...
Weekly Biotech Roundup: Top Insights From X's Best Accounts
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
Gene Therapy Poised to Redefine Obesity Treatment Landscape
1/GLP-1 obesity and weight-loss drugs - such as $NVO Ozempic & Wegovy and $LLY Zepbound & Mounjaro have long become a household name - making Obesity the fastest growing market in the BioTech and Pharma ecosystem and generating unprecedented revenues....
RA Capital Boosts Wave Stake Amid Clinical Setback
🚨Here is an interesting report from this week’s @barronsonline regarding a major investment made in $WVE by RA Capital - despite Wave’s recent disappointing clinical readout of its obesity candidate $WVE-007 🧵👇. According to the report RA Capital has raised...
BeamTx's Risto‑cel Shows Promising Phase
1/@BeamTx announced the publication of clinical data from its Phase 1/2 BEACON clinical trial evaluating risto-cel - formerly known as $BEAM-101 for the treatment of sickle cell disease (SCD). The data was presented at #ASH25 🧵👇 & was published in...
FDA Grants RMAT Status to Caribou’s Anti‑BCMA CAR‑T Therapy
1/🚨@CaribouBio announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 - $CRBU allogeneic anti-BCMA CAR-T Cell Therapy for treating relapsed or refractory multiple myeloma (r/r MM) cancer which is being evaluated in the CaMMouflage...
Biogen Buys Apellis for $5.6B, Adds SYFOVRE Sales‑linked CVR
1/Another mega M&A deal in the BioTech and Pharma sector with the acquisition of Apellis Pharmaceuticals - $APLS by Biogen $BIIB for $41 per share in cash at closing in a $5.6B deal. In addition, Apellis stockholders will also receive...
Gates Foundation Funds TesseraTx's Gene‑editing HIV Cure Research
1/🚨@TesseraTx has announced that it has received a grant from the Gates Foundation to fund an early-stage research which is aimed to develop a Gene Editing-based cure for HIV. This grant is build upon Tessera’s existing investment 🧵👇 from the Gates...
Weekly Biotech Roundup: Top Posts Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...
Elon Musk Shows True Leadership by Reversing Policy
Kudos to @elonmusk and @nikitabier for reviewing their decision🧵👇. When people make fun of my admiration for Elon Musk - here is example No. 203,321 as to why I think Elon is the greatest business leader of our lifetime. Elon’s...
X’s Regional Silencing Threatens Global Biotech Community
One major issue in 𝕏’s new regional silencing policy 🧵👇is that it will destroy many of the professional communities on 𝕏. Here is a relevant example for @nikitabier and @elonmusk - the BioTech community on 𝕏 includes many scientists, investors,...
Weekly Biotech Roundup: Top Insights Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
Eli Lilly Surges to #1 Pharma Sales in 2025
Another testimony of Eli Lilly’s increasing dominance in the BioTech and Pharma sector - compared to other Big Pharma companies - such as $PFE $JNJ $NVS $NVO $BMY $ABBV $MRK $SNY and others, can be seen in this excellent @NatRevDrugDisc...
Japan Leads Stem Cell Revolution Since Yamanaka’s 2006 Breakthrough
Not many are aware but Japan 🇯🇵 is a true powerhouse when it comes to Stem Cells research & the field of regenerative medicine since 2006 - when stem-cell biologist Shinya Yamanaka, working at Japan’s @KyotoU_News identified a handful of...
